Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Nutriband Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NUTRIBAND'S ACTIVE INTELLIGENCE SUBSIDIARY TO SHOWCASE EXPANDING AI WELLNESS PRODUCT PORTFOLIO AND NEW JUNE PRODUCT LAUNCHES AT ECRM CONFERENCE COMPANY TO MEET WITH BUYERS FROM WALMART INC, WALGREENS, AMAZON.COM, INC., CARDINAL HEALTH AND OTHER MAJOR NATIONAL RETAILERS ORLANDO, FLA., MAY 15, 2026 (GLOBE NEWSWIRE) -- NUTRIBAND INC. (NASDAQ:NTRB)(NASDAQ:NTRBW) AND ITS WHOLLY OWNED SUBSIDIARY ACTIVE INTELLIGENCE (ACTIVE INTELLIGENCE OR THE COMPANY), AN EMERGING LEADER IN INNOVATIVE WELLNESS, RECOVERY, AND PERFORMANCE-FOCUSED CONSUMER PRODUCTS, TODAY ANNOUNCED ITS PARTICIPATION IN THE UPCOMING ECRM CONFERENCE TAKING PLACE IN JUNE 2026, WHERE THE COMPANY WILL SHOWCASE ITS LATEST AI-BRANDED PRODUCT PORTFOLIO TO BUYERS AND EXECUTIVES FROM SOME OF THE NATION'S LARGEST RETAIL AND HEALTHCARE ORGANIZATIONS.

NUTRIBAND INC TO SHOWCASE EXPANDING AI WELLNESS PRODUCT PORTFOLIO AND NEW JUNE PRODUCT LAUNCHES AT ECRM CONFERENCE

ORLANDO, FLA., APRIL 22, 2026 (GLOBE NEWSWIRE) -- NUTRIBAND INC. (NASDAQ:NTRB)(NASDAQ:NTRBW), TODAY ANNOUNCED THAT ITS CEO AND CO-FOUNDER, GARETH SHERIDAN HAS FEATURED ON THE LATEST EPISODE OF THE JACK NEEL PODCAST TO DISCUSS THE OPIOID CRISIS, THE COMPANY'S AVERSA TECHNOLOGY AND THE OPPORTUNITY FOR NUTRIBAND TO IMPROVE THE SAFETY PROFILE OF EASILY ABUSED MEDICATIONS.

NUTRIBAND CEO, GARETH SHERIDAN DISCUSSES THE US FENTANYL CRISIS AND COMPANY UPDATE ON LATEST EPISODE OF THE JACK NEEL PODCAST

NUTRIBAND HAS SELECTED THE COMMERCIAL WORLDWIDE BRAND NAME FOR ITS LEAD PRODUCT, AN ABUSE DETERRENT FENTANYL TRANSDERMAL SYSTEM, AND WILL SUBMIT TO THE FDA FOR APPROVAL PER FDA GUIDANCE. NUTRIBAND PARTNERED WITH BRAND INSTITUTE, INC, THE GLOBAL LEADER IN PHARMACEUTICAL AND HEALTHCARE-RELATED BRAND NAME AND IDENTITY DEVELOPMENT.

NUTRIBAND SELECTS COMMERCIAL BRAND NAME FOR ITS ABUSE DETERRENT FENTANYL PATCH

ORLANDO, FLA., FEB. 17, 2026 (GLOBE NEWSWIRE) -- NUTRIBAND INC. (NASDAQ: NTRB) (NASDAQ: NTRBW) TODAY ANNOUNCED THAT IT HAS SIGNED AN EXCLUSIVE DISTRIBUTION AGREEMENT WITH COSTA RICA BASED INNOMEDICA FOR AVERSA FENTANYL UPON APPROVAL AND ALL SPORTS TAPE PRODUCTS MANUFACTURED AT ITS POCONO PHARMACEUTICAL / ACTIVE INTELL SUBSIDIARY.

NUTRIBAND SIGNS EXCLUSIVE DISTRIBUTION AGREEMENT WITH INNOMEDICA FOR AVERSA FENTANYL AND ALL SPORTS TAPE PRODUCTS FOR COSTA RICA

ORLANDO, FLA., JAN. 30, 2026 (GLOBE NEWSWIRE) -- NUTRIBAND INC. (NASDAQ: NTRB) (NASDAQ: NTRBW) HAS PROVIDED AN UPDATE TO SHAREHOLDERS ON THE KEY MILESTONES AND DISCUSSIONS FROM THIS YEARS ANNUAL SHAREHOLDERS MEETING, HELD ON JAN 24, 2026 IN ORLANDO, FLORIDA.

NUTRIBAND INC. PROVIDES SUMMARY OF ANNUAL SHAREHOLDER MEETING KEY DISCUSSION POINTS

ORLANDO, FLA., DEC. 31, 2025 (GLOBE NEWSWIRE) -- NUTRIBAND INC. (NASDAQ:NTRB) (NASDAQ:NTRBW) TODAY ANNOUNCED THAT CEO GARETH SHERIDAN HAS PUBLISHED A LETTER TO SHAREHOLDERS PROVIDING INSIGHTS ON ACHIEVEMENTS AND MILESTONES THROUGH 2025 AND THE POTENTIAL OUTLOOK FOR 2026.

NUTRIBAND CEO PUBLISHES LETTER TO SHAREHOLDERS

EARTHVISION BIO, IS CURRENTLY DEVELOPING AND COMMERCIALIZING ITS LINE OF SUSTAINABLE PRODUCTS DEVELOPED BY DR. GORDON MOORE, THE FOUNDER OF INTEL, AND DR. HANS FRANKE, EX-CHAIRMAN FOR CHEVRON EUROPE NUTRIBAND INC. SHAREHOLDERS WILL RETAIN 10% OF THE SHAREHOLDING IN EARTH VISION BIO FOLLOWING THE ACQUISITION THE EXPECTED CLOSING DATE FOR THE TRANSACTION IS DEC 31, 2025. ORLANDO, FLA.

NUTRIBAND INC. SIGNS AGREEMENT TO SELL MAJORITY STAKE OF SUBSIDIARY POCONO PHARMACEUTICAL FOR $5M USD TO EARTHVISION BIO

PRESCRIPTION PHARMACEUTICAL TRANSDERMAL FENTANYL IS A VALUABLE TREATMENT FOR MANAGEMENT OF PAIN IN OPIOID-TOLERANT PATIENTS, SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT FOR WHICH ALTERNATE TREATMENT OPTIONS ARE INADEQUATE. ILLICIT FENTANYL AND ITS CORE PRECURSOR CHEMICALS HAVE BEEN DESIGNATED AS WEAPONS OF MASS DESTRUCTION TO ENABLE THE US GOVERNMENT TO COMBAT THE MANUFACTURE AND DISTRIBUTION BY CARTELS AND FOREIGN NETWORKS THAT HAVE FLOODED THE US WITH ILLEGAL FENTANYL.

NUTRIBAND DIFFERENTIATES PRESCRIPTION FENTANYL FROM ILLICIT FENTANYL IN RESPONSE TO UNITED STATES EXECUTIVE ORDER DESIGNATING FENTANYL AS A WEAPON OF MASS DESTRUCTION

ORLANDO, FLORIDA--(NEWSFILE CORP. - NOVEMBER 24, 2025) - NUTRIBAND INC. (NASDAQ: NTRB) (NASDAQ: NTRBW), TODAY ANNOUNCED THAT ITS CHAIRMAN AND CO-FOUNDER, SERGUEI MELNIK WILL PRESENT AT NOBLECON21 - NOBLE CAPITAL MARKETS' TWENTY FIRST ANNUAL EMERGING GROWTH EQUITY CONFERENCE AT FLORIDA ATLANTIC UNIVERSITY, EXECUTIVE EDUCATION COMPLEX, IN BOCA RATON, FL.- ON WEDNESDAY, DECEMBER 3RD AT 9.30 AM EASTERN STANDARD TIME.

NUTRIBAND INC. TO PRESENT AT THE 2025 NOBLE CAPITAL MARKETS EMERGING GROWTH EQUITY CONFERENCE

NUTRIBAND MET WITH US FDA TO OBTAIN FEEDBACK ON THE CHEMISTRY, MANUFACTURING, AND CONTROLS PLANS FOR AVERSA FENTANYL (ABUSE DETERRENT TRANSDERMAL SYSTEM) THROUGH COMMERCIALIZATION. NUTRIBAND RECEIVED FINAL MEETING MINUTES FROM FDA AND IS INCORPORATING THE FEEDBACK INTO THE DEVELOPMENT PROGRAM AS IT MOVES FORWARD TO AN IND FILING IN SUPPORT OF A HUMAN ABUSE POTENTIAL (HAP) CLINICAL STUDY FOR THE PRODUCT.

Nutriband Inc.

NTRB

Price

Financial Reports

No items found.

Press Releases

Nutriband Inc.

NTRB.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

NTRB